Viking Therapeutics (VKTX) Income towards Parent Company (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Income towards Parent Company came in at -$128.1 million in Q2 2026, down 95.38% year-over-year from -$2.8 billion in Q2 2025, and up 19.12% quarter-over-quarter from -$158.3 million in Q1 2026.
Powered by 
Analysis
Viking Therapeutics (VKTX) Income towards Parent Company (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Income towards Parent Company across 13 years of filings, most recently posting -$128.1 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 95.38% year-over-year to -$128.1 million; the TTM figure through Jun 2026 stood at -$534.9 million (down 211.76% YoY), while the FY2025 annual figure was -$359.6 million, down 227.0% from the prior year.
- Income towards Parent Company came in at -$128.1 million for Q2 2026 at Viking Therapeutics, up from -$158.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$15.7 million in Q3 2022 to a low of -$158.3 million in Q1 2026.
- Average Income towards Parent Company over 5 years is -$50.6 million, with a median of -$24.8 million recorded in 2023.
- Year-over-year, Income towards Parent Company fell 10.44% in 2023 and slumped 345.56% in 2025.
- Over 5 years, Income towards Parent Company stood at -$19.6 million in 2022, then fell by 25.72% to -$24.6 million in 2023, then tumbled by 44.0% to -$35.4 million in 2024, then sank by 345.56% to -$157.7 million in 2025, then grew by 18.8% to -$128.1 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$128.1 million in Q2 2026, -$158.3 million in Q1 2026, and -$157.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -128.05 Mn |
| Mar 31, 2026 | -158.33 Mn |
| Dec 31, 2025 | -157.70 Mn |
| Sep 30, 2025 | -90.79 Mn |
| Jun 30, 2025 | -65.54 Mn |
| Mar 31, 2025 | -45.61 Mn |
| Dec 31, 2024 | -35.39 Mn |
| Sep 30, 2024 | -25.03 Mn |
| Jun 30, 2024 | -22.23 Mn |
| Mar 31, 2024 | -27.33 Mn |
| Dec 31, 2023 | -24.58 Mn |
| Sep 30, 2023 | -22.53 Mn |
| Jun 30, 2023 | -19.19 Mn |
| Mar 31, 2023 | -19.50 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -15.75 Mn |
| Jun 30, 2022 | -17.38 Mn |
| Mar 31, 2022 | -17.14 Mn |
| Dec 31, 2021 | -12.35 Mn |
| Sep 30, 2021 | -13.28 Mn |
API Access
Viking Therapeutics Income towards Parent Company API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-towards-parent-company", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();